Last reviewed · How we verify
norelgestromin + ethinyl estradiol; triphasil.
Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.
Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg. Used for Contraception.
At a glance
| Generic name | norelgestromin + ethinyl estradiol; triphasil. |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | contraceptive |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
Norelgestromin is a progestin that inhibits ovulation by suppressing the release of gonadotropin-releasing hormone, while ethinyl estradiol is an estrogen that thickens cervical mucus and changes the uterine lining to prevent implantation. This combination of actions prevents pregnancy.
Approved indications
- Contraception
Common side effects
- Nausea
- Headache
- Breast tenderness
- Mood changes
- Vaginal bleeding irregularities
Key clinical trials
- A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED) (PHASE4)
- Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
- A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: